Short-Term Results of Combined Radioimmunotherapy in Inoperable Lung Cancer

Curcio, C. Gallo; Vasile, Corina Maria; Gianciotta, Antonio; Casali, A; Gionfra, T; Rinaldi, Massimo; Guadagni, Alfredo D.; Pera, V.; Sega, E

doi:10.1177/030089167606200602

Cited by 4 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The targeted radionuclide therapy is based on the use of high-affinity molecules as carriers of radionuclides to tumor cells [ 1 ]. Pharmaceuticals for targeted radionuclide therapy are often injected intravenously or intracavitary.…”

Section: Introductionmentioning

confidence: 99%

Targeted Radionuclide Therapy of Human Tumors

Gudkov

Shilyagina

Vodeneev

et al. 2015

IJMS

150

111

View full text Add to dashboard Cite

Targeted radionuclide therapy is one of the most intensively developing directions of nuclear medicine. Unlike conventional external beam therapy, the targeted radionuclide therapy causes less collateral damage to normal tissues and allows targeted drug delivery to a clinically diagnosed neoplastic malformations, as well as metastasized cells and cellular clusters, thus providing systemic therapy of cancer. The methods of targeted radionuclide therapy are based on the use of molecular carriers of radionuclides with high affinity to antigens on the surface of tumor cells. The potential of targeted radionuclide therapy has markedly grown nowadays due to the expanded knowledge base in cancer biology, bioengineering, and radiochemistry. In this review, progress in the radionuclide therapy of hematological malignancies and approaches for treatment of solid tumors is addressed.

show abstract

Section: Introductionmentioning

confidence: 99%

Targeted Radionuclide Therapy of Human Tumors

Gudkov

Shilyagina

Vodeneev

et al. 2015

IJMS

150

111

View full text Add to dashboard Cite

show abstract

“…theranostics | targeted therapy | combined therapy | nuclear medicine | upconversion nanoparticles T argeted therapy makes use of high-affinity molecules as carriers of therapeutic agents, such as radioactive isotopes or toxins, to tumor cells (1)(2)(3)(4). Targeted therapy drugs are often administered intravenously, eventually homing to target molecules on the surface of tumor cells (5,6).…”

mentioning

confidence: 99%

Radioactive ( ⁹⁰ Y) upconversion nanoparticles conjugated with recombinant targeted toxin for synergistic nanotheranostics of cancer

Guryev

Volodina

Shilyagina

et al. 2018

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

We report combined therapy using upconversion nanoparticles (UCNP) coupled to two therapeutic agents: beta-emitting radionuclide yttrium-90 (Y) fractionally substituting yttrium in UCNP, and a fragment of the exotoxin A derived from genetically fused with a targeting designed ankyrin repeat protein (DARPin) specific to HER2 receptors. The resultant hybrid complex UCNP-R-T was tested using human breast adenocarcinoma cells SK-BR-3 overexpressing HER2 receptors and immunodeficient mice, bearing HER2-positive xenograft tumors. The photophysical properties of UCNPs enabled background-free imaging of the UCNP-R-T distribution in cells and animals. Specific binding and uptake of UCNP complexes in SK-BR-3 cells was observed, with separateY- and PE40-induced cytotoxic effects characterized by IC 140 μg/mL (UCNP-R) and 5.2 μg/mL (UCNP-T), respectively. When both therapeutic agents were combined into UCNP-R-T, the synergetic effect increased markedly, ∼2200-fold, resulting in IC = 0.0024 μg/mL. The combined therapy with UCNP-R-T was demonstrated in vivo.

show abstract